Cargando…
Diagnostic biomarkers for pancreatic cancer: An update
Pancreatic ductal adenocarcinoma accounts for the primary type of pancreatic cancer (PC) with a 5-year survival rate of only about 10% in the United States. Early diagnosis will improve chances for curative treatment. To date, a broadly used serum marker for PC diagnosis is carbohydrate antigen 19-9...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661384/ https://www.ncbi.nlm.nih.gov/pubmed/34963749 http://dx.doi.org/10.3748/wjg.v27.i45.7862 |
_version_ | 1784613358367932416 |
---|---|
author | Yang, Ming Zhang, Chun-Ye |
author_facet | Yang, Ming Zhang, Chun-Ye |
author_sort | Yang, Ming |
collection | PubMed |
description | Pancreatic ductal adenocarcinoma accounts for the primary type of pancreatic cancer (PC) with a 5-year survival rate of only about 10% in the United States. Early diagnosis will improve chances for curative treatment. To date, a broadly used serum marker for PC diagnosis is carbohydrate antigen 19-9, which is the only approved biomarker currently by the United States Food and Drug Administration. However, it has low specificity; therefore, development of novel biomarkers is urgently needed. Clinical trials are ongoing to evaluate candidate biomarkers for PC diagnosis, and the use of a multi-biomarker panel with current PC diagnostic biomarkers appears promising. |
format | Online Article Text |
id | pubmed-8661384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-86613842021-12-27 Diagnostic biomarkers for pancreatic cancer: An update Yang, Ming Zhang, Chun-Ye World J Gastroenterol Letter to the Editor Pancreatic ductal adenocarcinoma accounts for the primary type of pancreatic cancer (PC) with a 5-year survival rate of only about 10% in the United States. Early diagnosis will improve chances for curative treatment. To date, a broadly used serum marker for PC diagnosis is carbohydrate antigen 19-9, which is the only approved biomarker currently by the United States Food and Drug Administration. However, it has low specificity; therefore, development of novel biomarkers is urgently needed. Clinical trials are ongoing to evaluate candidate biomarkers for PC diagnosis, and the use of a multi-biomarker panel with current PC diagnostic biomarkers appears promising. Baishideng Publishing Group Inc 2021-12-07 2021-12-07 /pmc/articles/PMC8661384/ /pubmed/34963749 http://dx.doi.org/10.3748/wjg.v27.i45.7862 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Letter to the Editor Yang, Ming Zhang, Chun-Ye Diagnostic biomarkers for pancreatic cancer: An update |
title | Diagnostic biomarkers for pancreatic cancer: An update |
title_full | Diagnostic biomarkers for pancreatic cancer: An update |
title_fullStr | Diagnostic biomarkers for pancreatic cancer: An update |
title_full_unstemmed | Diagnostic biomarkers for pancreatic cancer: An update |
title_short | Diagnostic biomarkers for pancreatic cancer: An update |
title_sort | diagnostic biomarkers for pancreatic cancer: an update |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661384/ https://www.ncbi.nlm.nih.gov/pubmed/34963749 http://dx.doi.org/10.3748/wjg.v27.i45.7862 |
work_keys_str_mv | AT yangming diagnosticbiomarkersforpancreaticcanceranupdate AT zhangchunye diagnosticbiomarkersforpancreaticcanceranupdate |